Anesthesiology Research Analysis
May 2026 anesthesiology research converged on automation, organ protection, and patient-centered perioperative strategies. High-impact RCTs and meta-analyses refined fluid therapy and recovery pathways, while new pharmacology addressed mental-health and behavioral comorbidities (esketamine for depressive symptoms; semaglutide reducing heavy drinking). Reinforcement learning and closed-loop systems advanced automation with non-inferior safety, and individualized hemodynamics revealed domain-speci
Summary
May 2026 anesthesiology research converged on automation, organ protection, and patient-centered perioperative strategies. High-impact RCTs and meta-analyses refined fluid therapy and recovery pathways, while new pharmacology addressed mental-health and behavioral comorbidities (esketamine for depressive symptoms; semaglutide reducing heavy drinking). Reinforcement learning and closed-loop systems advanced automation with non-inferior safety, and individualized hemodynamics revealed domain-specific neurocognitive benefit. Translational ferroptosis inhibition showed promise for graft preservation during machine perfusion, and genomics flagged anesthesia safety risks that can guide agent selection.
Selected Articles
1. Hydroxyethyl Starch and Perioperative Complications: a Systematic Review and Meta-analysis.
Pooling 114 trials (13,951 patients), modern HES (130/0.4–0.42), typically used for <24 h in surgical settings, did not increase AKI (RR 1.02) or worsen creatinine change; no meaningful increases in adverse events or mortality were detected.
Impact: Large contemporary synthesis directly informs perioperative fluid safety and may recalibrate regulatory and institutional policies regarding modern HES in surgical patients.
Clinical Implications: Modern HES can be considered within short-duration goal-directed fluid therapy for non-critically ill surgical patients; avoidance remains prudent in sepsis/critical illness.
Key Findings
- No AKI signal with HES 130/0.4–0.42 (RR 1.02 [0.91–1.16]).
- Perioperative creatinine change was non-inferior; information size adequate by trial sequential analysis.
- No meaningful increase in adverse events or mortality; most use limited to <24 h.
2. Effect of intraoperative esketamine on moderate-to-severe depressive symptoms in major surgery patients: a randomized clinical trial.
A multicenter, double-blind RCT (n=435) showed intraoperative esketamine significantly increased remission of moderate-to-severe depressive symptoms on postoperative day 3 (28.3% vs 11.3%; OR 3.12) without changing acute pain; dissociative effects require monitoring.
Impact: Introduces a pragmatic intraoperative intervention with rapid psychiatric benefit, addressing a prevalent yet underrecognized perioperative burden.
Clinical Implications: Incorporate structured screening for perioperative depression and consider intraoperative esketamine with postoperative psychiatric monitoring when appropriate.
Key Findings
- Esketamine increased 3-day remission (28.3% vs 11.3%; OR 3.12).
- No group difference in acute postoperative pain.
- Higher incidence of dissociative/psychotomimetic effects necessitates monitoring.
3. Implementation and Effectiveness of an Enhanced Recovery Protocol for Children Undergoing Surgery: The ENRICH-US Stepped-Wedge Cluster-Randomized Trial.
An 18-site stepped-wedge cluster RCT (n=597) found no phase-level LOS reduction overall, but high patient-level fidelity (≥13 ERP elements) was associated with shorter LOS (−1.14 days) and fewer complications (aOR 0.48), underscoring the importance of implementation quality.
Impact: Shifts the ERAS discussion from efficacy to implementation science, providing multisite evidence that fidelity mediates clinical benefit in pediatrics.
Clinical Implications: Deploy fidelity-focused strategies (order-set integration, dashboards, learning collaboratives) to realize LOS/complication benefits when implementing pediatric ERPs.
Key Findings
- No overall LOS reduction by phase despite improvements in opioid use and time to diet.
- High-fidelity delivery (≥13 elements) shortened LOS by −1.14 days.
- High fidelity correlated with order-set integration and institutional culture.
4. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
A 26-week randomized, double-blind trial (n=108) showed once-weekly semaglutide 2.4 mg significantly reduced heavy drinking days versus placebo and improved multiple secondary outcomes, with mainly mild-to-moderate gastrointestinal adverse events.
Impact: High-quality RCT demonstrating GLP-1 receptor agonism reduces heavy drinking in obese AUD, expanding perioperative optimization levers for behavioral/metabolic risk.
Clinical Implications: Consider GLP-1 agonists as adjuncts for obese AUD patients in preoperative optimization pathways, pending broader validation and regulatory guidance.
Key Findings
- Heavy drinking days reduced vs placebo (−13.7 percentage points; 95% CI −22.0 to −5.4; p=0.0015).
- Multiple secondary alcohol-related and somatic outcomes improved.
- Adverse events mainly mild-to-moderate gastrointestinal; 81% completed treatment.
5. Ferroptosis inhibition enhances liver and lung graft function.
Translational work identified early lipid peroxidation in human liver transplants and showed that a ferroptosis inhibitor (FXT-001) preserved graft viability in porcine ex situ perfusion and split ex vivo perfusion of declined human lungs; next-generation inhibitors (FXT-002/003) exhibited improved PK and safety.
Impact: Provides mechanistic, multi-model evidence that targeting ferroptosis can protect grafts during preservation, with potential to change machine perfusion practice pending clinical trials.
Clinical Implications: If validated clinically, ferroptosis inhibitors could be integrated into perfusion protocols to improve graft quality and expand the donor pool across transplant types.
Key Findings
- Early transient lipid peroxidation identified in human liver transplants.
- FXT-001 preserved viability in porcine liver/lung ex situ and human lung ex vivo perfusion.
- Next-generation inhibitors (FXT-002/003) showed improved PK and safety profiles.